Biotech stock Alumis<\/strong> (ALMS) surged more than 110% on Tuesday after the company released strong clinical data for its plaque psoriasis drug, envudeucitinib, putting it squarely in competition with established and emerging players in the immunology space.<\/p>\n\n\n\n Envudeucitinib is an oral therapy that works by selectively blocking TYK2, a kinase that plays a key role in immune system regulation. In late-stage trials, approximately 65% of patients treated for 24 weeks achieved a 90% reduction in plaque psoriasis symptoms, while more than 40% reached complete skin clearance. These results place envudeucitinib among the most effective oral therapies reported to date in this category.<\/p>\n\n\n\n The data suggest Alumis may be able to challenge treatments from Johnson & Johnson<\/strong> (JNJ) and Protagonist Therapeutics<\/strong> (PTGX), whose drug icotrokinra targets IL-23, as well as Takeda Pharmaceutical<\/strong>\u2019s (TAK) TYK2 inhibitor, zasocitinib. Leerink Partners analyst Thomas Smith said the results appear competitive with other late-stage oral psoriasis programs and could reduce risk across additional inflammatory indications where TYK2 plays a role.<\/p>\n\n\n\n Importantly, patients responded quickly. Clear separation from placebo was seen as early as week four, supporting the potential for class-leading efficacy. Alumis Chief Medical Officer Jorn Drappa described the data as demonstrating \u201cthe full promise of TYK2 inhibition.\u201d<\/p>\n\n\n\n Safety also appeared favorable. Most side effects were mild to moderate and manageable with standard care, including headaches, colds, upper respiratory infections, and acne.<\/p>\n\n\n\n Alumis plans to submit its application to the Food and Drug Administration<\/strong> in the second half of 2026. With rivals set to present detailed data later this year, investors are now watching closely as envudeucitinib sets up what could be a defining competitive battle in psoriasis treatment.<\/p>\n\n\n\n